Our Resources

Virtual clinical trials aren’t just a buzzword—these research models are here to stay. In fact, the global market for virtual clinical trials is expected to reach $12.9 billion by 2030, according to Grand View Research.

This study sought to monitor COVID-19 prevalence and course of symptoms among oncology patients in order to identify any correlations with the biological and clinical data collected from the oncology cohort.

A multi-national European pharmaceutical and consumer health company required clinical data to validate the safety and performance of five of its nasal spray and allergy products post CE-mark, in accordance with MDR 2017/745 Annex XIV Part B.

Capturing and assessing patient-reported outcomes is key to driving patient centricity in healthcare research and delivery. However, the life sciences industry has frequently struggled to gather adequate, high-quality participant data in clinical trials, resulting in costly delays for study teams.

A multinational food and beverage company sought to analyze the prevalence of functional gastrointestinal disorders (FGIDs) and the efficacy of FGID treatments for Thai infants and toddlers.

Studying a medical device for the treatment of overactive bladder. ObvioHealth is conducting an innovative study seeking FDA approval of a wearable neuromodulation device for the treatment of overactive bladder (OAB).

Lycored, a leader in carotenoid-based wellness products, sought to understand the consumer-perceived efficacy of a tomato-based supplement through twelve subjective skin indicators.

In this post, we provide a comprehensive breakdown of the key challenges and opportunities associated with virtual clinical trials, examining the nuances of virtual components and how their implementation might affect each stage and touchpoint of the clinical trial journey.